Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer

Journal of Pathology

Volumn 187, Issue 2, 1999, Pages 237-241

  Koivisto, Pasi A ^a   Rantala, Immo ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Androgen receptor gene; Fluorescence in situ hybridization; Hormonal therapy; Immunohistochemistry; P53

Indexed keywords

ANDROGEN RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; RECURRENT CANCER;

AGED; DISEASE PROGRESSION; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032935293     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:2<237::AID-PATH224>3.0.CO;2-I     Document Type: Article

References (34)

1. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324: 236-245.
2. Scardino PT, Beck JR, Miles BJ. Conservative management of prostate cancer. N Engl J Med 1994; 330: 1831.
3. Greyhack J, Keeler T, Kozlowski J. Carcinoma of the prostate: hormonal therapy. Cancer 1987; 60: 589-601.
4. Klein L. Prostatic carcinoma. N Engl J Med 1979; 300: 824-833.
5. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993; 16: 475-492.
6. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi O-P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152: 1-9.
7. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 1997; 57: 314-319.
8. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
9. Chen P-L, Chen Y, Bookstein R, Lee W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-1580.
10. Culotta E, Koshland DE Jr. p53 sweeps through cancer research. Science 1993; 262: 1958-1959.
11. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
12. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
13. Fukasawa K, Choi T, Kuriyama R, Rulong S, van de Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996; 271: 1744-1747.
14. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
15. UICC. TNM. Classification of Malignant Tumours. Berlin: Springer-Verlag, 1987.
16. Mostofi FK. Histological Typing of Prostate Tumours. Geneva: World Health Organisation, 1980.
17. Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi O-P, Isola J. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry 1994; 16: 93-99.
18. Viskorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 1995; 9: 401-406.
19. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996; 48: 971-979.
20. Gumerlock PH, Chi SG, Shi XB, et al. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Co-operative Prostate Network. J Natl Cancer Inst 1997; 89: 66-71.
21. Schlechte HH, Schnorr D, Loning T, Rudolph BD, Pohrt UM, Loening SA. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - investigation by temperature gradient gel electrophoresis (TGGE). J Urol 1997; 157: 1049-1053.
22. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 883-887.
23. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-3373.
24. Mottaz AE, Markwalder R, Fey MF, et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 1997; 31: 209-215.
25. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151: 1276-1280.
26. Berner A, Nesland JM, Waehre H, Slide J, Fossa SD. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. Br J Cancer 1993; 68: 380-384.
27. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-1669.
28. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-421.
29. Berner A, Geitvik G, Karlsen F, Fossa SD, Nesland JM, Borresen AL. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. J Pathol 1995; 176: 299-308.
30. Eyfjörd JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ögmundsdottir HM, Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995; 55: 646-651.
31. Koivisto P, Hyytinen E, Palmberg C, Visakorpi T, Isola J, Kallioniemi O-P. FISH analysis of genetic changes underlying recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995; 147: 1608-1614.
32. Koivisto P, Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostatic Dis 1997; 1: 21-25.
33. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase gene in methotrexate-resistant variants of murine cells. J Biol Chem 1978; 253: 1357-1370.
34. Göker E, Waltham M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoplastic leukemia and is correlated with p53 gene mutations. Blood 1995; 86: 677-684.